Industry News
Biotechnology Industry News
BioMarin’s $270 million bet on…
BioMarin’s $270 million bet on Inozyme’s enzyme replacement therapy looks in trouble after the candidate only managed to hit one of the dual primary endpoints of a phase 3 study in children with a rare
After launching a hunt for…
After launching a hunt for strategic alternatives in January following a phase 3 rare disease flop, Quince Therapeutics has landed on an exit strategy. The Bay Area biotech has announced a merger with a private
Regeneron has ponied up $125…
Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on a new type of antibody-drug conjugate that could have better luck binding to tricky target sites.
Vincentage Pharma’s oral GLP-1…
Vincentage Pharma’s oral GLP-1 agonist has been tied to a mean weight loss of 12.4% over a year, setting up the biotech to pursue Eli Lilly’s orforglipron to Chinese regulators.
Ipsen has shared phase 2 data on…
Ipsen has shared phase 2 data on its long-acting neurotoxin, reporting an increase in the proportion of people with significant improvements in frown lines 24 weeks after treatment.
It’s time to kick off our annual…
It's time to kick off our annual hunt for the latest crop of trailblazing biotechs that we sense are going to shape the industry of the future.
A phase 3 trial of Regeneron’s…
A phase 3 trial of Regeneron’s LAG-3 inhibitor has missed its primary endpoint, leaving the biopharma reeling from the second failure of a key late-stage program in the past year.
After a series of staff…
After a series of staff consolidation moves in recent weeks, Novartis is again trimming its ranks, albeit in what appears to be a more limited move centered on the Swiss drugmaker’s biomedical research arm.
Alumis is exploring strategic…
Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than pursue the phase 3 program envisaged before it acquired the asset.
Aardvark Therapeutics is planning…
Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome program after the FDA put a full clinical hold on its studies.
“Outliers are what you’re going…
“Outliers are what you're going for,” Model Medicines CEO Daniel Haders, Ph.D., told Fierce to explain the company's AI-driven drug development strategy.
There are critical reasons why the…
There are critical reasons why the industry’s brightest minds are picking Ohio to innovate, collaborate, and make the biggest impact with their work.
Andrea Pfeifer, Ph.D., the…
Andrea Pfeifer, Ph.D., the longtime leader of Swiss neurodegeneration outfit AC Immune, is retiring from the C-suite to spend more time with her family. Pfeifer will be replaced in the interim by board chair Martin
Discover how Cognition…
Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies with innovative, accessible therapies.
NAMs have momentum, but adoption…
NAMs have momentum, but adoption still lags. Learn what’s holding them back and what it will take to move forward.
As the wave of in vivo CAR-T hype…
As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back its early pipeline of autoimmune and cancer candidates.
A phase 2 trial of Biogen and…
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose-response data, reductions in tau pathology and cognitive benefits
Regenxbio’s gene therapy for…
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a win for a biotech that has struggled in recent months under the weight of a rejection and
Aptose Biosciences has scrapped a…
Aptose Biosciences has scrapped a deal for a blood cancer drug candidate as part of its pending takeover by Hanmi Pharmaceutical.
After axing its lead obesity asset…
After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses.